Ulrika Birgersdotter-Green

Jan 5, 2025 | medrxiv.org | Troy Jackson |Ulrika Birgersdotter-Green |Yong-Mei Cha |Robert Taepke

The authors have declared no competing interest. Medtronic, Inc. was the sole funding support for data collection and analysis. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB required. Only De-identified data was included in the analysis.

Sep 12, 2024 | radcliffecardiology.com | Blandine Mondésert |Ulrika Birgersdotter-Green

Overview This session covers the latest data on transvenous and subcutaneous ICD devices, focusing on shared decision-making and their practical applications in preventing sudden cardiac death. Moderated by Dr Blandine Mondésert (Montreal Heart Institute and University of Montreal, CA) and Dr Ulrika Birgersdotter-Green (University of California San Diego, US), this webinar delves into the long-term benefits and innovations in Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) therapy.

Dec 11, 2023 | healio.com | Ulrika Birgersdotter-Green |Richard Smith

You've successfully added Cardiology: Practice Management to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Ionizing radiation has traditionally posed risks for cardiologists who use X-ray machines.

Dec 4, 2023 | onlinelibrary.wiley.com | Bradley P. Knight |Nicolas Clementy |Anish Amin |Ulrika Birgersdotter-Green

1 INTRODUCTION Implantable cardioverter-defibrillator (ICD) therapy is associated with a mortality benefit for patients at risk for sudden cardiac death.1-4 Understanding the costs of ICD therapy involves not only the costs of initial implantation but also the ongoing costs related to standard device follow-up, generator changes for battery depletion, and the management of device-related complications over the life of the patient. Innovations in ICD technology can impact these costs.